This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

We recently published a list of Jim Cramer Discussed These 18 Stocks After Major AI Event. In this article, we are going to ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has filed for a $100M initial ...

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...

Wall Street will first parse the producer price index for December on Tuesday, followed by the consumer price index on ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?